Metraipolis › archive › dc_7ece120ee4fe

Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster… — Europe PMC PMID:35289719

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/35289719
DOI
10.1080/19420862.2022.2047144
License (as archived)
CC0-1.0
Archived
2026-10-31T18:12:18.232Z
SHA-256 of the archived text
77fd35fa77e2ca9f3d754eaf95d790d42df4e86663ee3b0a39a7e37c78453bab
Stable URL of this page
https://metraipolis.com/documento/dc_7ece120ee4fe

How to cite

Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster… — Europe PMC PMID:35289719 — Europe PMC (en), https://europepmc.org/article/MED/35289719 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7ece120ee4fe (Metraipolis archive dc_7ece120ee4fe, sha256 77fd35fa77e2ca9f3d754eaf95d790d42df4e86663ee3b0a39a7e37c78453bab)
BibTeX
@misc{dc7ece120ee4fe,
  title = {Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster… — Europe PMC PMID:35289719},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/35289719},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7ece120ee4fe; sha256 77fd35fa77e2ca9f3d754eaf95d790d42df4e86663ee3b0a39a7e37c78453bab},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/35289719. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

There remains an unmet need for globally deployable, low-cost therapeutics for the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Previously, we reported on the isolation and in vitro characterization of a potent single-domain nanobody, NIH-CoVnb-112, specific for the receptor-binding domain (RBD) of SARS-CoV-2. Here, we report on the molecular basis for the observed broad in vitro neutralization capability of NIH-CoVnb-112 against variant SARS-CoV-2 pseudoviruses. The structure of NIH-CoVnb-112 bound to SARS-CoV-2 RBD reveals a large contact surface area overlapping the angiotensin converting enzyme 2 (ACE2) binding site, which is largely unencumbered by the common RBD mutations. In an in vivo pilot study, we demonstrate effective reductions in weight loss, viral burden, and lung pathology in a Syrian hamster model of COVID-19 following nebulized delivery of NIH-CoVnb-112. These findings support the further development of NIH-CoVnb-112 as a potential adjunct preventative therapeutic for the treatment of SARS-CoV-2 infection. Abbreviations: ACE2 - angiotensin converting enzyme 2BSA - buried surface areaCDR - complementary determining regionRBD - receptor binding domainRBM - receptor-binding motifSARS-CoV-2 - severe acute respiratory syndrome coronavirus 2.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: mAbs, 2022 (prima pubblicazione 2022-01-01).
Identificativi: PMID 35289719 · PMCID PMC8928829 · DOI 10.1080/19420862.2022.2047144.
Parole chiave degli autori: Single-domain antibody; Covid-19; Sars-cov-2; Nebulized Delivery; Neutralizing Nanobody.
Pagina: https://europepmc.org/article/MED/35289719 — https://doi.org/10.1080/19420862.2022.2047144. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-31T18:04:19.871Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.